The deal priced below last closing price of $2.28. Goldman Sachs, Jefferies and TD Cowen are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
- Allogene Therapeutics price target raised to $9 from $7 at Baird
- Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
- Allogene Therapeutics price target raised to $8 from $5 at Citizens
- Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments